AbbVie Ends Partnership With BioArctic in Parkinson’s Disease
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement…
Summary : Researchers at Karolinska Institutet in Sweden have developed a novel strategy for identifying potent miniature antibodies, so-called nanobodies, against emerging…
Summary : OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced that early biomarker analyses from the ongoing Phase 1 clinical trial with SIRPα…
Summary : AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at…
Summary : British biotech company Scancell has expanded its research and development capabilities at one of the UK’s leading parks for science…
Summary : The Committee for Medicinal Products for Human Use (CHMP) has provided an initial assessment of Valneva’s inactivated, adjuvanted COVID-19 vaccine…
Summary : Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will…
Summary : A new study shows why certain NK cells are activated when encountering a cell infected with SARS-CoV-2. The infected cells…
Synopsis: For at least six months after COVID-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted…
It’s uncertain if we will ever determine the origins of COVID-19. The current top theories split about evenly between a lab leak from…